Successful Performance of Roche’s Experimental Weight Loss Pill

🌍 Roche announced that in an early-phase study, its experimental pill named CT-996, which is taken once daily, led to a 6.1% weight loss in non-diabetic obese patients over four weeks.

🌍 This experimental pill, which could be attractive to patients averse to injections, was well-tolerated with gastrointestinal side effects mostly mild to moderate, similar to those seen with other weight loss medications.

🌍 In December 2023, Roche acquired Carmot Therapeutics for $2.7 billion, including the CT-996 drug, thus joining the ranks of weight loss medication developers.